Ultragenyx Pharmaceutical Inc. (RARE)
Nasdaq · Healthcare · Biotechnology
$14.50−4.73%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $1.4B
- Forward P/E
- 21.4
- 52-week range
- $12.73 – $39.89
- 52-week change
- −48.82%
- EPS (trailing)
- −$5.55
- Analyst rating
- 2.0 Buy
- Next earnings
- Nov 3, 2026
Fiscal year to Dec 2025
- Revenue
- $673M (+20.18%)
- Net income
- −$575M
- Operating margin
- −79.5%
- Diluted EPS
- −$5.83
- Free cash flow
- −$472M
From the company’s annual report on SEC EDGAR.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
Headquarters: Novato, United States · 1,371 employees · ultragenyx.com